Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group

作者： J. Gilbert , J. Lee , A. Argiris , L. Feldman , M. Haigentz

DOI: 10.1200/JCO.2009.27.15_SUPPL.6020

关键词:

摘要: 6020 Background: B, inhibits activation of NF- κβ and growth SCCHN cell lines. NF-κβ dysregulation contributes to chemoresistance, including I. Pretreatment with B increases tumor sensi...

ascopubs.org 本地加速

sci-hub.st HTML 下载加速

参考文章(0)

Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group

来源期刊

我的账户

Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group

来源期刊

相似文章 6

Thérapeutiques moléculaires ciblées en oncologie ORL

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.

Molecular targeted therapies in all histologies of head and neck cancers: an update.

Emerging therapies for head and neck cancer: review of the Phase II and III trials

Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.

Molecular biology of squamous cell carcinoma of the head and neck : relevance and therapeutic implications

我的账户